Access to High Cost Medicines: An Overview

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

High-cost medicines (HCMs) have been largely defined based on monetary value because of their potential to increase pharmaceutical spending for either the individual patient or healthcare systems. One of the biggest challenges encountered by many healthcare systems around the globe is to provide equitable access to HCMs while maintaining the sustainability of systems that are already constrained in resources. The global medicine spending is expected to increase with growing use of HCMs for an increasing number of diseases. Many newly developed medicines that offer therapeutic advantages for a range of diseases are reported to be efficacious, but are expensive for healthcare systems and/or patients compared to traditional medicines. Country’s wealth and/or affordability of the healthcare system has a direct relationship with patients’ access to HCMs. The developed markets are better resourced than developing countries and therefore are more likely to meet the demands for access to and use of HCMs. Nevertheless, all countries are facing the challenges of rationing and prioritising access to HCMs. Disproportional access to HCMs, particularly in nations where patient out-of-pocket costs largely support their treatment, might be particularly concerning
LanguageEnglish
Title of host publicationEquitable Access to High-Cost Pharmaceuticals
PublisherElsevier
Chapter1
Pages1-10
Number of pages10
ISBN (Electronic)978-0-12-811945-7
Publication statusPublished - 2 Mar 2018

Fingerprint

Costs and Cost Analysis
Delivery of Health Care
Traditional Medicine
Health Expenditures
Developing Countries
Medicine
Therapeutics
Pharmaceutical Preparations

Cite this

Hasan, S. S., Lu, C., & Babar, Z-U-D. (2018). Access to High Cost Medicines: An Overview. In Equitable Access to High-Cost Pharmaceuticals (pp. 1-10). Elsevier.
Hasan, Syed Shahzad ; Lu, Christine ; Babar, Zaheer-Ud-Din. / Access to High Cost Medicines : An Overview. Equitable Access to High-Cost Pharmaceuticals. Elsevier, 2018. pp. 1-10
@inbook{bfb3e528cb1d447f9431d8996b56ec90,
title = "Access to High Cost Medicines: An Overview",
abstract = "High-cost medicines (HCMs) have been largely defined based on monetary value because of their potential to increase pharmaceutical spending for either the individual patient or healthcare systems. One of the biggest challenges encountered by many healthcare systems around the globe is to provide equitable access to HCMs while maintaining the sustainability of systems that are already constrained in resources. The global medicine spending is expected to increase with growing use of HCMs for an increasing number of diseases. Many newly developed medicines that offer therapeutic advantages for a range of diseases are reported to be efficacious, but are expensive for healthcare systems and/or patients compared to traditional medicines. Country’s wealth and/or affordability of the healthcare system has a direct relationship with patients’ access to HCMs. The developed markets are better resourced than developing countries and therefore are more likely to meet the demands for access to and use of HCMs. Nevertheless, all countries are facing the challenges of rationing and prioritising access to HCMs. Disproportional access to HCMs, particularly in nations where patient out-of-pocket costs largely support their treatment, might be particularly concerning",
author = "Hasan, {Syed Shahzad} and Christine Lu and Zaheer-Ud-Din Babar",
year = "2018",
month = "3",
day = "2",
language = "English",
pages = "1--10",
booktitle = "Equitable Access to High-Cost Pharmaceuticals",
publisher = "Elsevier",

}

Hasan, SS, Lu, C & Babar, Z-U-D 2018, Access to High Cost Medicines: An Overview. in Equitable Access to High-Cost Pharmaceuticals. Elsevier, pp. 1-10.

Access to High Cost Medicines : An Overview. / Hasan, Syed Shahzad; Lu, Christine; Babar, Zaheer-Ud-Din.

Equitable Access to High-Cost Pharmaceuticals. Elsevier, 2018. p. 1-10.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Access to High Cost Medicines

T2 - An Overview

AU - Hasan,Syed Shahzad

AU - Lu,Christine

AU - Babar,Zaheer-Ud-Din

PY - 2018/3/2

Y1 - 2018/3/2

N2 - High-cost medicines (HCMs) have been largely defined based on monetary value because of their potential to increase pharmaceutical spending for either the individual patient or healthcare systems. One of the biggest challenges encountered by many healthcare systems around the globe is to provide equitable access to HCMs while maintaining the sustainability of systems that are already constrained in resources. The global medicine spending is expected to increase with growing use of HCMs for an increasing number of diseases. Many newly developed medicines that offer therapeutic advantages for a range of diseases are reported to be efficacious, but are expensive for healthcare systems and/or patients compared to traditional medicines. Country’s wealth and/or affordability of the healthcare system has a direct relationship with patients’ access to HCMs. The developed markets are better resourced than developing countries and therefore are more likely to meet the demands for access to and use of HCMs. Nevertheless, all countries are facing the challenges of rationing and prioritising access to HCMs. Disproportional access to HCMs, particularly in nations where patient out-of-pocket costs largely support their treatment, might be particularly concerning

AB - High-cost medicines (HCMs) have been largely defined based on monetary value because of their potential to increase pharmaceutical spending for either the individual patient or healthcare systems. One of the biggest challenges encountered by many healthcare systems around the globe is to provide equitable access to HCMs while maintaining the sustainability of systems that are already constrained in resources. The global medicine spending is expected to increase with growing use of HCMs for an increasing number of diseases. Many newly developed medicines that offer therapeutic advantages for a range of diseases are reported to be efficacious, but are expensive for healthcare systems and/or patients compared to traditional medicines. Country’s wealth and/or affordability of the healthcare system has a direct relationship with patients’ access to HCMs. The developed markets are better resourced than developing countries and therefore are more likely to meet the demands for access to and use of HCMs. Nevertheless, all countries are facing the challenges of rationing and prioritising access to HCMs. Disproportional access to HCMs, particularly in nations where patient out-of-pocket costs largely support their treatment, might be particularly concerning

UR - https://www.elsevier.com/books/equitable-access-to-high-cost-pharmaceuticals/babar/978-0-12-811945-7

M3 - Chapter

SP - 1

EP - 10

BT - Equitable Access to High-Cost Pharmaceuticals

PB - Elsevier

ER -

Hasan SS, Lu C, Babar Z-U-D. Access to High Cost Medicines: An Overview. In Equitable Access to High-Cost Pharmaceuticals. Elsevier. 2018. p. 1-10